Navigation Links
Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
Date:7/21/2010

SHELTON, Conn., July 21 /PRNewswire/ -- Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $15 million.  The round was led by new investor, Rho Ventures, with participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi International Corporation and MVM Life Science Partners. In conjunction with the financing, Martin Vogelbaum, a partner at Rho Ventures, will join Cara's Board of Directors. The Series D financing will be used primarily for the continued clinical development of Cara's lead peripherally restricted kappa opioid agonist, CR845, for the treatment of post-operative pain.  Cara has raised more than $43M since inception.

"There has been little innovation in post-operative pain treatment where opioid use continues to be the standard of care even though it is associated with significant side effects which present an ongoing pharmacoeconomic burden for hospitals.  Due to its peripheral activity and lack of CNS penetration, we believe Cara's CR845 has a chance to provide opioid-like pain relief while significantly reducing opioid use and its associated side effects," said Martin Vogelbaum, partner at Rho Ventures.  "We have been impressed with the progress that the Cara team have made to date with CR845 and look forward to working with them as CR845 progresses through the clinic."

"We are very pleased to welcome Rho Ventures as our newest investor and we look forward to benefiting from Martin's considerable experience as we continue the clinical development of CR845," said Derek Chalmers, President and CEO of Cara Ther
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 BioLineRx (NASDAQ: ... biopharmaceutical company dedicated to identifying, in-licensing and developing ... commenced an underwritten public offering of American Depositary ... Ordinary Shares. All of the ADSs in the ... JMP Securities is acting as sole ...
(Date:3/5/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... its financial results for the fourth quarter and full ... , Net Revenues Increased 21.3% Year Over Year to ... 17.7% Year Over Year to $140.5 Million , ...
(Date:3/5/2015)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 2015.  , Revenues were $11.8 million in the ... up 11% from $10.6 million in the 2013 fourth quarter. ... 12% from $38.3 million in 2013. , Gross margin ... in the fourth quarter of the prior year. , ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
(Date:3/6/2015)... 06, 2015 In a new study conducted ... patients reported that shoulder pain was their first mesothelioma symptom. ... website. Click here to read it now. , ... medical records of 49 mesothelioma patients between 2006 ... it was shoulder pain that first prompted them to see ...
(Date:3/6/2015)... 06, 2015 FCPX developers have ... Film Studios. , “Pro3rd Hue is a lower 3rd pack ... of Pixel Film Studios. “Blurring the line between professional and ... Hue is a set of 30 customizable lower third presets ... Pro3rd Hue, FCPX users can complement any design with a ...
(Date:3/6/2015)... 06, 2015 Fluid Running® Owner, Jennifer ... developed the Fluid Running® method 3 years ... Chicago marathon. She hit upon the trifecta of combining ... and a maximum-resistance, deep water running technique. She not ... deep water running workout that made the experience both ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as host ... dates include the following activities:, October ... October 6: Conference Day 1, ending with a Fashion Show ... ending with Local Entertainment and Dinner , October ... Meetings , October 9-10: Textiles in India Tour ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 ... of formaldehyde in low-cost laminate flooring products, ... leading manufacturer of eco-friendly building materials made primarily ... safety by testing all their flooring products for ... detection laboratory Benchmark International (BMH). Results ...
Breaking Medicine News(10 mins):Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2
... to a recent,study(1), more than 6.1 million Americans ... plans, a 35 percent increase since,last year. Consumers ... accounts (FSAs) to cut costs associated with health ... nationwide, is making it easier for shoppers enrolled ...
... MT. LAUREL, N.J., June 18 After 25 years, ... Association (DNA) is,on the brink of a new era. ... thousands of non-members alike can read the latest news,and ... brand-new,publication will be available, in its entirety, online, offering ...
... Martin promoted to lead College Living Experience, ... (ESA) today announced Stephanie Martin has been appointed ... (CLE), an ESA,program that helps students with autism ... be responsible for all operations, clinical, behavioral and,curricular ...
... /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or the ... leading provider of,pharmacy benefits management services, announces that ... the Jefferies 2nd Annual Healthcare,Conference in New York ... 24, 2008 at 11:45 am ET., SXC,s ...
... Florida department of urology officials signed an agreement ... CureVac to test an experimental therapy for advanced ... traditional treatment. , CureVac which specializes in ... that transfers genetic information from nuclear DNA to ...
... 150,000 Identities, ANDOVER, Mass., June 18 ... seven healthcare organizations have selected,Sentillion,s proVision solution to ... challenges of manual user account,management, including:, ... Baptist Health System (Birmingham, AL) -- Hawaii ...
Cached Medicine News:Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 2Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 3Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 4Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 2Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 3Health News:Educational Services of America Names a New Senior VP of Operations 2Health News:UF scientists to work with German firm in prostate cancer treatment research 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: